Needham Maintains Buy on Trevi Therapeutics, Raises Price Target to $24
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $22 to $24.
Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $22 to $24.